Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Applied filters
Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_III | Pages 397 - 397
1 Jul 2010
Parsons S Starks I Bancroft G Baker C Roberts P
Full Access

Introduction: The national comparative audit in 2007 of blood use in primary elective hip replacement, showed a 25% transfusion rate. Of those 93% received two or more units. Orthopaedic surgeons are large users of blood, so reducing blood use, should save costs and reduce risk from unnecessary donor exposure.

Methods: Over two years 221 consecutive primary total hip replacements were performed, on 84 male and 137 female patients, average age 70 years (42–91yrs). For each the Haematinics cell salvage system was used. Throughout the surgery the cell salvage system was used. At the end of the operation all swabs were washed, the washings were salvaged. Iodine/peroxide contaminated washing and swabs were discarded.

Results: Were we using blood at the level suggested by the comparative audit, 55 patients would have received an average of 2.4 units (132 units total). The actual number of patients transfused was 12, receiving an average of two units (24 units total). This is 108 units less with 43 fewer patients receiving allogenic blood. Using a test of proportions using the Normal distribution then the significance probability is extremely small (SP< 0.001) indicating that this group of patients had a significantly smaller number of transfusions than would be expected compared with the National Average. The transfused patients were older (78.9 vs. 69.8, p< 0.01), had a greater Hb drop (45 g/l vs. 31.2 g/l, p< 0.01), had a lower pre-op Hb (121.3 g/l vs. 138 g/l, p< 0.001), and a greater length of stay (12.8 days vs. 5.8 days, p< 0.05). Gender was not significant.

Discussion: Using the cell salvage system leads to a significant reduction in allogenic blood use. It may not be cost neutral once the use of disposables is factored in, but may represent a useful tool to cost effectively reduce allogenic blood use.